Literature DB >> 26582411

From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency.

A Cremer1, F Amraoui2, G Y H Lip3, E Morales4, S Rubin1, J Segura4, B J Van den Born2, P Gosse1.   

Abstract

The prevalence of malignant hypertension has clearly fallen with the advent of anti-hypertensive medication but has remained stable over the past 30-40 years in spite of progress in diagnosis and management of hypertension. A diagnosis of malignant hypertension is usually based on the association of severely elevated blood pressure with a Keith and Wagener stage III or IV retinopathy. We believe that this definition can be reconsidered for several reasons. Although simple and pragmatic, this definition corresponds to a time when there were few techniques for assessment of hypertensive target organ involvement, and does not take into account involvement of kidney, brain and heart; whereas the overall prognosis largely depends on how much they are affected. On the contrary, the acute blood pressure level and especially diastolic should not be a hard diagnostic criterion as it does not itself constitute the prognosis of the condition. We propose to consider that malignant hypertension with retinopathy is only one of a number of possible presentation(s) of acute hypertension with multi organ damage (hypertension multi organ damage (MOD)) and that the recognition of these hypertensive emergencies, when retinopathy is lacking, be based on acute elevation of BP associated with impairment of at least three different target organs. The objective of a new and expanded definition is to facilitate recognition of these true emergencies. The condition is more common than usually perceived and would have a much worse prognosis than the usual forms of hypertension. Early recognition and management of hypertension-MOD are fundamental to any improvement in prognosis.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26582411     DOI: 10.1038/jhh.2015.112

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  23 in total

1.  Hypertension: treated and untreated; a study of 400 cases.

Authors:  A W LEISHMAN
Journal:  Br Med J       Date:  1959-05-30

2.  Long-term renal survival in malignant hypertension.

Authors:  Roberto González; Enrique Morales; Julian Segura; Luis M Ruilope; Manuel Praga
Journal:  Nephrol Dial Transplant       Date:  2010-03-17       Impact factor: 5.992

3.  Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model.

Authors:  Karen A Griffin; Aaron Polichnowski; Natalia Litbarg; Maria Picken; Manjeri A Venkatachalam; Anil K Bidani
Journal:  Hypertension       Date:  2014-06-23       Impact factor: 10.190

4.  Lack of difference between malignant and accelerated hypertension.

Authors:  M E Ahmed; J M Walker; D G Beevers; M Beevers
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-25

5.  Ethnic disparities in the incidence, presentation and complications of malignant hypertension.

Authors:  Bert-Jan H van den Born; Richard P Koopmans; Johan O Groeneveld; Gert A van Montfrans
Journal:  J Hypertens       Date:  2006-11       Impact factor: 4.844

6.  Impact of malignant arterial hypertension on the heart.

Authors:  Philippe Gosse; Paul Coulon; Georgios Papaioannou; Jean Litalien; Philippe Lemetayer
Journal:  J Hypertens       Date:  2011-04       Impact factor: 4.844

7.  A comprehensive assessment of cardiac structure and function in patients with treated malignant phase hypertension: the West Birmingham Malignant Hypertension project.

Authors:  Alena Shantsila; Girish Dwivedi; Eduard Shantsila; Mehmood Butt; D Gareth Beevers; Gregory Y H Lip
Journal:  Int J Cardiol       Date:  2011-12-20       Impact factor: 4.164

8.  Does renal function improve after diagnosis of malignant phase hypertension?

Authors:  G Y Lip; M Beevers; D G Beevers
Journal:  J Hypertens       Date:  1997-11       Impact factor: 4.844

Review 9.  Acute hypertension: a systematic review and appraisal of guidelines.

Authors:  Kirk J Pak; Tian Hu; Colin Fee; Richard Wang; Morgan Smith; Lydia A Bazzano
Journal:  Ochsner J       Date:  2014

10.  Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study.

Authors:  Fouad Amraoui; Niels V Van Der Hoeven; Irene G M Van Valkengoed; Liffert Vogt; Bert-Jan H Van Den Born
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-12-27       Impact factor: 3.738

View more
  21 in total

1.  C5b9 Formation on Endothelial Cells Reflects Complement Defects among Patients with Renal Thrombotic Microangiopathy and Severe Hypertension.

Authors:  Sjoerd A M E G Timmermans; Myrurgia A Abdul-Hamid; Judith Potjewijd; Ruud O M F I H Theunissen; Jan G M C Damoiseaux; Chris P Reutelingsperger; Pieter van Paassen
Journal:  J Am Soc Nephrol       Date:  2018-06-01       Impact factor: 10.121

2.  Malignant hypertension as a rare cause of thrombotic microangiopathy.

Authors:  Guramrinder Thind; Karthik Kailasam
Journal:  BMJ Case Rep       Date:  2017-06-08

3.  Clinical value of multiorgan damage in hypertensive crises: A prospective follow-up study.

Authors:  Hongkun Ma; Mengdi Jiang; Zongjie Fu; Zhiyu Wang; Pingyan Shen; Hao Shi; Xiaobei Feng; Yongxi Chen; Xiaoyi Ding; Zhiyuan Wu; Wen Zhang
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-04-09       Impact factor: 3.738

Review 4.  Eclectic Ocular Comorbidities and Systemic Diseases with Eye Involvement: A Review.

Authors:  María D Pinazo-Durán; Vicente Zanón-Moreno; José J García-Medina; J Fernando Arévalo; Roberto Gallego-Pinazo; Carlo Nucci
Journal:  Biomed Res Int       Date:  2016-03-14       Impact factor: 3.411

5.  20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats.

Authors:  Lenka Sedláková; Soňa Kikerlová; Zuzana Husková; Lenka Červenková; Věra Čertíková Chábová; Josef Zicha; John R Falck; John D Imig; Elzbieta Kompanowska-Jezierska; Janusz Sadowski; Vojtěch Krátký; Luděk Červenka; Libor Kopkan
Journal:  Biosci Rep       Date:  2018-09-12       Impact factor: 3.840

6.  Malignant hypertension: does this still exist?

Authors:  Magdalena Domek; Jakub Gumprecht; Gregory Y H Lip; Alena Shantsila
Journal:  J Hum Hypertens       Date:  2019-10-21       Impact factor: 3.012

7.  Does established vascular kidney disease exist?

Authors:  Nicolás Roberto Robles; Francesco Fici; Elif Ari Bakir; Guido Grassi
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-01-31       Impact factor: 3.738

8.  Relationship between kidney findings and systemic vascular damage in elderly hypertensive patients without overt cardiovascular disease.

Authors:  Giulio Geraci; Giuseppe Mulè; Gabriella Paladino; Marta Maria Zammuto; Antonella Castiglia; Emilia Scaduto; Federica Zotta; Calogero Geraci; Antonio Granata; Pasquale Mansueto; Santina Cottone
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-11-29       Impact factor: 3.738

9.  Concurrent analogous organ damage in the brain, eyes, and kidneys in malignant hypertension: reversible encephalopathy, serous retinal detachment, and proteinuria.

Authors:  Eikan Mishima; Yukino Funayama; Takehiro Suzuki; Fumiko Mishima; Fumihiko Nitta; Takafumi Toyohara; Koichi Kikuchi; Hiroshi Kunikata; Junichiro Hashimoto; Mariko Miyazaki; Hideo Harigae; Toru Nakazawa; Sadayoshi Ito; Takaaki Abe
Journal:  Hypertens Res       Date:  2020-07-27       Impact factor: 3.872

10.  Renal resistive index and aortic knob width relationship as a predictor of renal prognosis in essential hypertension.

Authors:  Nurhayat Ozkan Sevencan; Aysegul Ertinmaz Ozkan
Journal:  Medicine (Baltimore)       Date:  2018-10       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.